Sector News

Alexion plans to appoint David Brennan to succeed Bell as Chairman

March 3, 2017
Life sciences

Alexion Pharmaceuticals Inc. announced, Leonard Bell, Founder of the company, has informed the Board that he will not stand for reelection as a Board member and will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders scheduled for May 10, 2017.

The Board announced that it expects to appoint David Brennan, Alexion’s Interim CEO and fellow Board member, to succeed Bell as Chairman.

Interim CEO David Brennan stated, “Since joining the Alexion Board of Directors in 2014 and being named Interim CEO late last year, I have gotten to know and deeply respect Lenny for the exceptional foresight and determination he so passionately brings to Alexion. The Board and I look forward to partnering with Alexion’s new CEO, once he or she is announced, to continue the company’s progress and to execute on our strategy as a leader and innovator in the global biopharmaceutical industry.”

Dr. Bell said, “I am incredibly proud of all that we have achieved over the past 25 years since Alexion was founded. I am very much looking forward to spending increasing time with my family, and also exploring new and different opportunities.”

Source: RTT News

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend